Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity
- PMID: 32524292
- DOI: 10.1007/s00432-020-03285-9
Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity
Abstract
Introduction: Biliary tract cancers (BTC) are rare malignancies arising from biliary system. Systemic therapy is the cornerstone for stage IV disease, with poor overall survival (OS). Evidence is lacking about safety and efficacy of local ablative treatments, such as surgery and stereotactic body radiotherapy (SBRT) in the context of metastatic BTC (mBTC).
Materials and methods: We retrospectively analyzed clinical outcomes for a cohort of mBTC patients treated with SBRT for oligometastatic disease. Inclusion criteria were 1-5 distant metastases; SBRT with a dose/fraction of a least 5 Gy to a biological effective dose (BED) of at least 40 Gy considering an α/β of 10 Gy. Analyzed outcomes included local control (LC), distant progression-free survival (DPFS), PFS, and OS.
Results: 51 patients meeting the inclusion criteria. Primary tumor sites were intrahepatic cholangiocarcinoma (35%), extrahepatic cholangiocarcinoma (31%), ampullary adenocarcinoma (20%), gallbladder adenocarcinoma (14%). 21 patients were treated on liver lesions, 17 on nodal metastasis, 5 patients on lung lesions, 4 patients on recurrence along the extrahepatic bile duct. After a median follow-up of 14 months median OS was 13.7 months, 1- and 2-year OS were 58% and 41%, respectively. Node and lung as metastatic sites were associated with a longer OS (p < 0.001). Median LC was 26.8 months, and intrahepatic cholangiocarcinoma was associated with longer LC (p = 0.036). Median DPFS was 11 months, with 1- and 2-year DPFS of 48% and 27.8%, respectively. Ten patients reported grade 1-2 toxicity and 2 cases of acute G3 biliary obstruction.
Conclusions: Stereotactic body radiotherapy (SBRT) is feasible in the context of mBTC. OS and PFS results are promising, considering that our patients were heavily pre-treated with systemic therapy. Patients with nodal or lung relapse have better prognosis. Distant relapses remain the main pattern of failure, but treatment of all metastatic sites seems to improve DMFS.
Keywords: Biliary tract cancer; Cholangiocarcinoma; Oligometastases; Radiotherapy; SABR; SBRT; Stereotactic body radiation therapy.
Similar articles
-
Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.BMC Cancer. 2017 Nov 21;17(1):781. doi: 10.1186/s12885-017-3788-1. BMC Cancer. 2017. PMID: 29162055 Free PMC article.
-
Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.Radiother Oncol. 2019 Mar;132:42-47. doi: 10.1016/j.radonc.2018.11.015. Epub 2018 Dec 20. Radiother Oncol. 2019. PMID: 30825968
-
Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".Lung Cancer. 2016 Jul;97:51-8. doi: 10.1016/j.lungcan.2016.04.012. Epub 2016 Apr 26. Lung Cancer. 2016. PMID: 27237028
-
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.BJU Int. 2019 Nov;124 Suppl 1:19-30. doi: 10.1111/bju.14886. Epub 2019 Sep 11. BJU Int. 2019. PMID: 31507035 Review.
-
Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma.World J Surg Oncol. 2022 Sep 29;20(1):322. doi: 10.1186/s12957-022-02781-1. World J Surg Oncol. 2022. PMID: 36171617 Free PMC article. Review.
Cited by
-
High dose proton and photon-based radiation therapy for 213 liver lesions: a multi-institutional dosimetric comparison with a clinical perspective.Radiol Med. 2024 Mar;129(3):497-506. doi: 10.1007/s11547-024-01788-w. Epub 2024 Feb 12. Radiol Med. 2024. PMID: 38345714 Free PMC article.
-
New trends in diagnosis and management of gallbladder carcinoma.World J Gastrointest Oncol. 2024 Jan 15;16(1):13-29. doi: 10.4251/wjgo.v16.i1.13. World J Gastrointest Oncol. 2024. PMID: 38292841 Free PMC article. Review.
-
Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century.Curr Oncol. 2023 Oct 19;30(10):9230-9243. doi: 10.3390/curroncol30100667. Curr Oncol. 2023. PMID: 37887567 Free PMC article. Review.
-
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada.Curr Oncol. 2023 Jul 25;30(8):7132-7150. doi: 10.3390/curroncol30080517. Curr Oncol. 2023. PMID: 37622998 Free PMC article.
-
Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC.Front Immunol. 2023 Jan 17;14:1084843. doi: 10.3389/fimmu.2023.1084843. eCollection 2023. Front Immunol. 2023. PMID: 36733485 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical